天津医药

天津医药 ›› 2015, Vol. 43 ›› Issue (4): 446-448.doi: 10.11958/j.issn.0253-9896.2015.04.031

• 综述 • 上一篇    

血管血栓性疾病的抗凝治疗及利伐沙班应用新进展

赵子源，张秀军△   

  1. 天津市天津医院血管外科（邮编300210）
  • 收稿日期:2014-05-09 修回日期:2014-12-09 出版日期:2015-04-15 发布日期:2015-04-13
  • 通讯作者: 张秀军 E-mail:zhangxiujun6180@126.com
  • 作者简介:赵子源（1978），男，主治医师，硕士，主要从事血管外科的临床研究

Anticoagulation therapy of vascular thrombotic diseases and new progress of Rivaroxaban application

ZHAO Ziyuan, ZHANG Xiujun△   

  1. Department of Vascular Surgery of Tianjin Hospital, Tianjin 300211, China
  • Received:2014-05-09 Revised:2014-12-09 Published:2015-04-15 Online:2015-04-13
  • Contact: ZHANG Xiujun E-mail:zhangxiujun6180@126.com

PDF (PC)

4155

摘要： 摘要：血栓性疾病的发病率极高，且具有很高的致残率和致死率，其预防和治疗主要针对抗血小板聚集、抗凝和溶栓等三个环节。抗血栓治疗方法的选择强调个体化原则。利伐沙班作为直接Ⅹa 因子抑制剂，不需要抗凝血酶Ⅲ 就能发挥其抗凝活性，且对凝血酶原复合物中的Ⅹa 因子无效，可作为传统抗凝剂的替代抗凝药。本文就利伐沙班治疗症状性静脉血栓疾病、术后静脉血栓形成、心血管系统血栓形成等临床应用综述如下。

关键词: 抗凝药, 因子Ⅹa, 血栓形成, 综述, 利伐沙班

Abstract: Abstract: Incidence of thrombotic disease is very high, and this disease can result in high mortality and high disability rate. Prevention and treatment of the disease mainly include: antiplatelet, anticoagulation and thrombolysis. Choice of anti⁃ thrombotic treatment based emphasizes on individuation. As a direct inhibitor of factor Xa, Rivaroxaban exert its anticoagu⁃ lant activity without antithrombin Ⅲ but is ineffective to the Ⅹa in prothrombin complex, which can be used as a substitute of traditional anticoagulant. In this paper, applications of Rivaroxaban on treating symptomatic venous thromboembolic dis⁃ ease, postoperative venous thrombosis and cardiovascular thrombosis are reviewed.

Key words: anticoagulants, factor Ⅹa, thrombosis, review, Rivaroxaban